Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Robert Cohen who wrote (1361)	5/25/2001 6:40:43 PM
From: Susan G	Respond to of 1477

U.S. FDA panel backs Scios heart failure drug Friday May 25, 6:12 pm Eastern Time biz.yahoo.com

To: Robert Cohen who wrote (1361)	5/26/2001 12:45:42 AM
From: keokalani'nui	Respond to of 1477

Robert: Thank you for your reply. >>It is most usual to relieve symptoms of shortness of breath within 1 hour<< It will be difficult to sell N to you and who knows how many others. According to VMAC, for shortness of breath, N was not better than IVG at 2 hours, but only eeked it out with significance at 3 hr., and then its success depended primarily on the catheterized patients to carry the statistical load. Though I'm very happy for SCIO, patients and investors, I'm a little disappointed. It's not as good as I first believed; and it looks like SCIO made it under the limbo stick basically by lowering the dose. Congrats to them, I hope its a blockbuster. Wilder

To: Robert Cohen who wrote (1361)	5/28/2001 2:42:33 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 1477

That N work better than NTG (which is toxic, btw) is clear to everyone except you (experienced emergency MD). NTG was used as control because of the N safety concern, and to see drug efficacy one more time. Hospitals and emergency rooms (including MDs) make money per days and treatment conditions, not what drugs they used. They will oppose new therapy as long as they can, period. N is used (tested) in addition to other CHF SOC drugs. Yes, N may be expensive drug, but drug economic not price will dictate market penetration. And, this is question which none of as can answer right now. Miljenko